Author/Authors :
Lv، نويسنده , , Fujia and Qiu، نويسنده , , Yuhe and Zhang، نويسنده , , Yaxi and Liu، نويسنده , , Shilian and Shi، نويسنده , , Juan and Liu، نويسنده , , Yanxin and Zheng، نويسنده , , Dexian، نويسنده ,
Abstract :
In the present study we demonstrate that adeno-associated virus (AAV)-mediated anti-DR5 (death receptor 5) mouse–human chimeric antibody (shorten as Adximab) expression significantly suppressed tumor cell growth by inducing apoptosis both in vitro and in vivo. The viral-expressed and cell-secreted Adximab efficiently bound DR5 with an affinity of 0.7 nM and induced apoptosis of various tumor cells, but not normal cells. A single intramuscular injection of recombinant AAV particles resulted in a stable expression of Adximab in mouse serum for at least 70 days. AAV-mediated Adximab expression led to a significant suppression of tumor growth in nude mice receiving xenografts of human liver and colon cancer. These data suggest that chimeric antibody gene transfer may provide an alternative strategy for the therapy of varieties of cancers.
Keywords :
Death receptor 5 , Gene transfer , Chimeric antibody , Cancer Therapy